migraine
Study Shows Atogepant Prevents Migraine In Difficult Cases
A recent study has shown that atogepant (Qulipta, AbbVie), may help prevent migraines in people who have had no ...
SEPTEMBER 12, 2023
FDA Approves Qulipta for Chronic Migraine
The FDA expanded the indication for Qulipta for the preventive treatment of migraine in adults.
APRIL 18, 2023
Test Predicts Response to Key Migraine Therapy With 86% Accuracy
A quick, inexpensive and noninvasive proprietary test is an 86% accurate pretreatment predictor of anti-calcitonin ...
MARCH 13, 2023
Post-op Delirium Lower in Patients With Pre-op Migraine Diagnosis
A preoperative diagnosis of migraine is associated with less postoperative delirium, a surprising finding from a ...
NOVEMBER 9, 2022
Intranasal Ketamine May Offer Relief for Headache Patients Who Have Exhausted Other Options
Intranasal ketamine is emerging as a clinical tool to address pain caused by chronic refractory migraine in ...
MAY 31, 2022
Pediatric Infusion Center Reduces Headache Pain, Payor Cost
A study has demonstrated the success of an infusion treatment to relieve acute headache and migraine in children.
SEPTEMBER 28, 2021
Metoclopramide Plus Diphenhydramine Effective in Headache Following Trauma
In cases of post-traumatic headache, metoclopramide plus diphenhydramine provided superior relief to placebo, ...
JULY 8, 2021
Despite Risks, Opioid Scripts Remain High For Migraine
A study assessing the value of opioids in treating migraine headaches has reconfirmed previous findings that the ...
FEBRUARY 17, 2020
FDA Approves New Acute Migraine Treatment
The FDA approved lasmiditan tablets for the acute treatment of migraine with or without aura in adults.
OCTOBER 16, 2019
FDA Approves Emgality for Migraine Prevention
The FDA approved galcanezumab-gnlm (Emgality, Eli Lilly) to prevent migraine in adults.
SEPTEMBER 28, 2018
FDA Approves Ajovy for Migraine Prevention
The FDA approved Ajovy, a humanized monoclonal antibody, for the prevention of migraine in adults.
SEPTEMBER 18, 2018
Aimovig Gets FDA Nod for Migraine Prevention
Aimovig is the first FDA-approved treatment to block the calcitonin gene–related peptide receptor, which ...
MAY 18, 2018
